Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Dürig
1875  Ergebnisse:
Personensuche X
?
1

Ibrutinib + bortezomib + R‐CHOP for higher‐risk DLBCL: Feas..:

Denker, S. ; Bittner, A. ; Frick, M....
Hematological Oncology.  41 (2023)  S2 - p. 424-425 , 2023
Link: https://doi.org/10.1002/..
 
?
2

HIGH RATE OF METABOLIC COMPLETE RESPONSE AFTER LOW DOSE RAD..:

Herfarth, K. ; Scholz, C. W. ; Hübel, K....
Hematological Oncology.  41 (2023)  S2 - p. 218-220 , 2023
Link: https://doi.org/10.1002/..
 
?
3

Covestro Monitoring Platform – Monitoring of Sensor, Asset,..:

Bamps, B. ; Dürig, D. ; Frenzel, P..
Chemie Ingenieur Technik.  94 (2022)  9 - p. 1317-1317 , 2022
Link: https://doi.org/10.1002/..
 
?
4

P879: EXENT AND FLC MASS SPECTROMETRY FOR SEROLOGICAL IDENT..:

Huhn, S. ; Poos, A. M. ; Mai, E. K....
HemaSphere.  6 (2022)  - p. 771-772 , 2022
Link: https://doi.org/10.1097/..
 
?
5

P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASON..:

Mai, E. K. ; Bertsch, U. ; Fenk, R....
HemaSphere.  6 (2022)  - p. 820-821 , 2022
Link: https://doi.org/10.1097/..
 
?
6

Richter transformation in chronic lymphocytic leukemia (CLL..:

Al-Sawaf, O. ; Robrecht, S. ; Bahlo, J....
Leukemia.  35 (2020)  1 - p. 169-176 , 2020
Link: https://doi.org/10.1038/..
 
?
7

POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE ..:

Dimopoulos, M. ; Weisel, K. ; Moreau, P....
Hematology, Transfusion and Cell Therapy.  42 (2020)  - p. 272-273 , 2020
Link: https://doi.org/10.1016/..
 
?
8

Is air pollution associated with adaptive immune responses,..:

B, Hoffmann ; S, Ohlwein ; F, Hennig...
Environmental Epidemiology.  3 (2019)  Supplement 1 - p. 160-160 , 2019
Link: https://doi.org/10.1097/..
 
?
9

UNMAINTAINED REMISSION AFTER DISCONTINUATION OF KINASE INHI..:

Egle, A. ; Jäger, U. ; Skrabs, C....
Hematological Oncology.  37 (2019)  S2 - p. 218-219 , 2019
Link: https://doi.org/10.1002/..
 
?
10

SAMHD1 IS FREQUENTLY INVOLVED IN T‐CELL PROLYMPHOCYTIC LEUK..:

Johansson, P. ; Klein‐Hitpass, L. ; Bergmann, A.K....
Hematological Oncology.  35 (2017)  S2 - p. 164-164 , 2017
Link: https://doi.org/10.1002/..
 
?
11

IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIO..:

Hiddemann, W. ; Barbui, A.M. ; Canales Albendea, M.A....
Hematological Oncology.  35 (2017)  S2 - p. 117-119 , 2017
Link: https://doi.org/10.1002/..
 
?
12

Circulating tumor cells as a biomarker for response to ther..:

Huhn, S ; Weinhold, N ; Nickel, J...
Bone Marrow Transplantation.  52 (2017)  8 - p. 1194-1198 , 2017
Link: https://doi.org/10.1038/..
 
?
13

DRUG PERTURBATION BASED STRATIFICATION OF LYMPHOPROLIFERATI..:

Dietrich, S. ; Oleś, M. ; Sellner, L....
Hematological Oncology.  35 (2017)  S2 - p. 56-56 , 2017
Link: https://doi.org/10.1002/..
 
?
14

Lenalidomide treatment and prognostic markers in relapsed o..:

Bühler, A ; Wendtner, C-M ; Kipps, T J...
Blood Cancer Journal.  6 (2016)  3 - p. e404-e404 , 2016
Link: https://doi.org/10.1038/..
 
?
15

Deorphanization and characterization of the ectopically exp..:

Manteniotis, S ; Wojcik, S ; Göthert, J R...
Cell Death Discovery.  2 (2016)  1 - p. , 2016
Link: https://doi.org/10.1038/..
 
1-15